Anti CD47 drugs are monoclonal antibodies that block signal regulatory protein Alpha (SIRPa), a receptor on macrophages and other immune cells. CD47 is a "don't eat me" signal protein expressed on various cell types, including cancer cells. By blocking this protein, anti-CD47 drugs enhance phagocytosis and clearance of cancer cells by macrophages and other phagocytes. The increasing prevalence of cancer around the world has boosted the demand for advanced treatment options like anti-CD47 drugs. The global cancer burden is expected to reach almost 27 million new cases per year by 2040. This rising cancer incidence rate presents a massive market opportunity for anti-CD47 drugs which have shown promising results in clinical trials for hematologic and solid tumors.
The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031..
Key players operating in the anti CD47 drugs market includes Trillium Therapeutics, Forty Seven Inc, Shanghai Legend Biotech, Inhibrx and Celgene. Trillium Therapeutics' lead candidate TWi Biotechnology currently in phase 1 clinical trials is emerging as a front runner in the market.
The increasing prevalence of cancer across the globe is a major factor driving the demand for novel and targeted Anti CD47 Drugs Market treatment options. Monoclonal antibodies that enhance phagocytosis of tumor cells offer potential with limited adverse effects compared to traditional chemotherapy or radiation therapy.
Constant technological advancements are expanding the possibilities for anti-CD47 drugs. Companies are developing next generation humanized anti-CD47 antibodies and bispecific antibodies combining anti-CD47 with other cancer antigens which may provide improved efficacy and safety profiles.
Market Trends
Growing focus on combination therapies: Researchers are exploring combination of anti-CD47 drugs with other immunotherapy drugs like checkpoint inhibitors or chemotherapeutic agents. Synergistic effects can potentially improve clinical outcomes.
Partnerships and acquisitions: Big pharma companies are investing and partnering with anti-CD47 focused biotechs to tap into this emerging novel modality. For instance, Celgene acquiredownership of SEATTLE GENETICS' anti-CD47 drug axatilimab in 2021.
Market Opportunities
Increasing R&D investments in China and Asia: China and other Asian countries are emerging as hotspots for clinical trials of anti-CD47 drugs given lower costs and large patient pools presenting lucrative opportunities.
Potential new indications: Beyond hematologic and solid tumors, anti-CD47 drugs offer promise in other cancers like lung, breast, ovarian, gastric and multiple myeloma. Success in early trials may lead to approval for additional cancer types.
Impact of COVID-19 on Anti CD47 Drugs Market
The COVID-19 pandemic has significantly impacted the growth of the anti CD47 drugs market. During the initial months of the outbreak when most nations imposed strict lockdowns, research activities slowed down significantly which hampered the clinical trials of various anti CD47 drugs in the pipeline. However, companies have now adapted to the new normal and are actively finding ways to continue their research work while ensuring safety. Virtual meetings and remote monitoring of clinical trials are being conducted on a large scale. Regulatory agencies have also fast-tracked approval processes for COVID-19 therapeutics which is likely to benefit anti-cancer therapies in the long run.
With the economic downturn weakening purchasing power, fundraising activities became difficult during 2020. However, venture capital investments started recovering in late 2020 and early 2021 as trials restarted. Various biotech firms have raised funding to advance their candidate drugs into late-stage clinical trials. The pandemic has highlighted the need for immunotherapies and this has increased focus on harnessing the immune system to treat cancer. Governments across major markets have announced stimulus packages for healthcare research which is expected to boost the market in the coming years.
North America accounts for the largest share of the anti CD47 drugs market in terms of value. The region is home to many key pharmaceutical companies and biotechs conducting clinical research. Availability of funding along with presence of advanced healthcare infrastructure makes North America an attractive location for clinical trials.
Asia Pacific is expected to be the fastest growing region for the anti CD47 drugs market during the forecast period. This can be attributed to rising cancer incidence, increasing healthcare spending by governments and expanding research capabilities in China, India and other Asian nations. Collaborations between global pharmaceutical companies and local Asian players are also likely to boost regional clinical research activities involving anti CD47 therapies in the upcoming years.
Get more insights on- Anti CD47 Drugs Market
Get this Report in Japanese Language: 抗CD47薬市場
Get this Report in Korean Language: 항 CD47 약물 시장
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
